Radetec Diagnostics is a Melbourne-based biotech company that developed a new way to produce highly-fluorescent nanoparticles called “quantum dots”, stable in buffers and that can be linked to several biologically-active molecules (e.g. antibodies). Quantum dots form the core of Radetec’s platform technology, enabling different applications in medical imaging, biomarker screening and sensing. Another key capability of Radetec Diagnostics is its optimisation of Lateral Flow Assays (LFAs), a market-proven solution for the production of rapid Point-Of-Care Tests (POCTs).
Radetec is using its own quantum dots to commercialise two POCTs based on lateral flow technology: a rapid multiplex test for Chlamydia and Gonorrhoea (the two most prevalent sexually transmitted infections worldwide) and a rapid antigen test for COVID-19. Radetec’s tests allow users to diagnose these diseases accurately, inexpensively, quickly and conveniently — something that is considered the ‘holy grail’ of infectious disease diagnosis and prevention.
The mission of Radetec Diagnostics is to contribute to the fight against Sexually Transmitted Infections and other infectious diseases such as COVID-19, improving the well-being of the society and helping in the elimination of prejudices and taboos. Radetec Diagnostics focuses on the global challenges of our time, aiming to achieve global impact with its ground-breaking rapid test technology and remove the barriers that get in the way of securing your health. Radetec Diagnostics is closely working with highly experienced partners, material suppliers and contract manufacturers around the world, to offer outstanding products and services, making difficult applications possible.
Radetec Diagnostic commercialise reagents and equipment for lateral flow assay development through its website LateralFlows.com. Our quantum dots technology can be licensed to third parties, to be integrated in their products. Visit our quantum dots page for more information about our technology.